Evidence map›Paper›PMID 40109455›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025

[Wogonoside Attenuates Hypertension-Induced Renal Injury Through Modulation of the MAPK Signaling Pathway: A Mechanism Study].

Zhi Guo, Yi Xie, Hongshu Liu, Jundan Xiao, Rongji Chen, Meizhu Wu, Jun Peng, Aling Shen

Abstract readEnglish Abstract
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Mechanism of Trifolin in Attenuating Hypertension-Induced Renal Cell Apoptosis via Modulation of the MAPK Signaling Pathway].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhi Guo( 350122) Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
Yi Xie( 350122) Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
Hongshu Liu( 350122) Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
Jundan Xiao( 350122) Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
Rongji Chen( 350122) Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
Meizhu Wu( 350122) Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
Jun Peng( 350122) Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
Aling Shen( 350122) Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the potential therapeutic effects, targets, and pathways of wogonoside in hypertension-induced renal injury using the Gene Expression Omnibus (GEO) database and network pharmacology, and to validate the effects of wogonoside intervention on the renal tissues of spontaneously hypertensive rats (SHR), angiotensin Ⅱ (Ang Ⅱ)-stimulated NRK-52E cell apoptosis, and the regulation of relevant pathways through Methods: GEO dataset and network pharmacology analyses were performed to investigate the key therapeutic targets of wogonoside for hypertensive nephropathy. The STRING database was used to analyze protein-protein interactions. Biological functions were annotated via Gene Ontology (GO), and the potential signaling pathways were enriched using the Kyoto Encyclopedia of Genes and Genomes (KEGG). SHR were randomly divided into groups and given low, medium, or high doses of wogonoside (0.075, 0.75, and 7.5 mg/kg) via gastric gavage for 10 weeks. Morphological changes in the kidney tissue were assessed by hematoxylin-eosin (HE) staining. Serum levels of inflammatory cytokines, including tumor necrosis factor α (TNF-α), interleukin (IL)-1β, and IL-6, were measured using ELISA. Apoptosis rates were evaluated by TUNEL staining, and Western blot was performed to determine the expression of Bax, Bcl-2, cleaved caspase-3, and caspase-3, and the expression of phosphorylated and total extracellular signal-regulated kinases (ERK) and p38 mitogen-activated protein kinase (MAPK) proteins. An Results: Analysis of dataset GSE41453 revealed 11673 upregulated and 5902 downregulated genes in the renal tissues of SHR compared to the Wistar Kyoto (WKY) rats, or the WKY control group. Through the analysis of multiple databases, 371 potential targets of wogonoside were identified, resulting in 98 overlapping targets. From these, 45 core therapeutic targets were identified through further analysis, including TNF, CASP3, etc. GO analysis significantly enriched processes such as the negative regulation of apoptosis. KEGG pathway enrichment analysis highlighted the apoptosis pathway, IL-17 signaling pathway, and MAPK signaling pathway as being significantly enriched. Wogonoside treatment effectively mitigated pathological damage in SHR kidney tissues and significantly inhibited the expression of inflammatory cytokines, including TNF-α, IL-1β, and IL-6 ( Conclusion: Wogonoside may exert its protective effects against hypertension-induced renal injury by suppressing the inflammatory response and cell apoptosis, potentially through the regulation of the MAPK signaling pathway.

Indexed as

FlavanonesGlucosidesHypertensionMAP Kinase Signaling SystemAngiotensin IIAnimalsApoptosisCell LineHypertension, RenalKidneyMaleNephritisRatsRats, Inbred SHRAngiotensin IIFlavanonesGlucosideswogonosideApoptosisGene Expression OmnibusHypertensive nephropathyNetwork pharmacologyWogonoside

Identifiers

PMID40109455
PMCPMC11914008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.